XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.54

-1.2%

11:26 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (8899)	3/2/1999 10:30:00 AM
From: Tharos	Read Replies (2) of 17367

*** FDA OKs mousse to treat psoriasis WASHINGTON (AP) - Patients who suffer psoriasis of the scalp won a slightly different kind of treatment Monday: a mousse-like foam to rub onto scalp lesions with less mess than traditional drugs. Until now, the main treatment has been a lotion containing the chemical betamethasone, but putting a lotion on the scalp every day is messy and greasy. The Food and Drug Administration approved Connetics Corp.'s new version of betamethasone, an easier-to-apply foam called Luxiq. An estimated 3.5 million Americans have scalp psoriasis, marked by redness, scaling, severe itching and irritation. In one study of 172 patients, 72% treated with Luxiq had complete or almost complete clearance of their psoriasis outbreak, compared with 47% who used a betamethasone lotion. Connetics said Luxiq will be available in about six weeks. A final price has not been set, but a spokeswoman said it would be about $50 to $60 for a 100-gram bottle.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next